April 11, 2024 8:35am

March’s PPI and a jobless claims report today

The Harvard Apparatus RT (OTCQB: HRGN) Chronicles: Question, has major shareholder and landlord, Harvard Bioscience (HBIO) in the midst of a lay-off; have been left holding a depreciating “bag” of shares (5% or 697,112 shares – SC 13G/A filing) from its $4 M share of the wrongful death lawsuit settlement having been issued 4,000 shares of series E 8% convertible Preferred stock at a price of $1,000 per share to satisfy the indemnification obligations (10-K)?  How will HBIO protect itself and its asset/balance sheet when and who will NOT finance this OTCQB: HRGN pig with this its lipstick and lingering odor?

Pre-open Indicators: 1 Positive and 2 Negative Indicators

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!

A string of reports showing inflation and the economy have remained hotter than expected has forced the “Street” to delay forecasts for when relief on rates could arrive

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility!

My version of the morning’s numbers is written to be informative; it’s including what happened or will happen beyond the headline and shapes today’s potential sector response as seen by RMi.

 

Thursday: The pre-open Dow futures are DOWN -0.44% or (-170 points), the S&P futures are DOWN -0.52% or (-27 points) as the Nasdaq futures are DOWN -0.40% or (-73 points)

Stock futures fell Thursday morning.

European markets were lower.

Asia-Pacific markets largely fell.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Wednesday: The Dow closed DOWN -422.16 points or -1.09%, the S&P closed -49.27 points or -0.95% while the Nasdaq closed DOWN -136.28 points or -0.84%

Economic Data Docket: Wholesale prices rose 0.2% in March, less than expected

  • Economists had expect wholesale prices to have grown by 0.3% in March, and 0.2% when excluding food and energy.
  • Separately, weekly jobless claims are also due before the bell.

 

Wednesday night’s RegMed Investors (RMi) Closing Bell: “the cell and gene therapy sector got chewed-up, bloods everywhere. After inflation data came in hotter than expected as the Nasdaq dipped 1.01%.” … https://www.regmedinvestors.com/articles/13412

 

Q2/24:  April - 6 negative and 2 positive closes

Q1/24:

  • March – 8 positive and 12 negative closes
  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Wednesday, Tuesday, Monday, Friday and last Thursday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Intellia Therapeutics (NTLA) closed down -$1.13 after Tuesday’s +$0.78 and Monday’s +$0.52 with a positive +$0.71 or +2.85% pre-open indication

 

Negative Indications:

Wednesday, Tuesday, Monday, Friday and last Thursday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

BioLife Solutions (BLFS) closed down -$0.90 after Tuesday’s +$0.85, Monday’s +$0.18, Friday’s -$0.38 with a negative -$0.04 or -0.23% pre-open indication.

Beam Therapeutics (BEAM) closed down -$2.26 after Tuesday’s +$0.51, Monday’s +$0.61, Friday -$0.83 and Thursday’s -$0.65 with a negative -$0.06 or -0,22% pre-open indication.

 

The BOTTOM LINE: bracing for another key inflation report … more bad news for equities?

Cell and gene therapy sector investors got pummeled Wednesday, as the advance /decline line (A/Dl) closed with 5 ups, 28 downs and 2 flats following 2 positive closes this week.

  • After a hotter-than-expected March inflation report that will likely force a major reset of Fed interest rate outlooks,
  • The harsh reaction, which also lifted benchmark 10-year Treasury-note yields to their highest levels since early November.

 

"This market touchiness should not be confused with directional weakness, which we are not seeing right now, as markets have been strong all year despite substantial changes in Fed rate-cut expectations and a mixed bag of returns … “. <David Bahnsen, chief investment officer at Bahnsen Group in Newport Beach, Calif.>

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.